Keele University Science & Innovation Park tenant celebrates 10 years of growth
The tenth anniversary was celebrated in Thea’s new offices at Keele University’s Science and Innovation Park. Previously tenants in Innovation Centre 3, the move to Innovation Centre 5 allows for further growth with modern facilities, on-site management and a range of support services from both the County Council and Keele University.
The event was attended by valued customers, suppliers, friends and members of the Thea UK team including Philip Lewis Williams, Managing Director of Thea UK. Alongside him was Jean-Frédéric Chibret, President of ‘Laboratoires Thea’ and Carlos Amador, Director of Business Operations for ‘Laboratoires Thea’. A plaque was unveiled in order to commemorate the special event.
Thea Pharmaceuticals is a family owned pharmaceutical company which develops, manufactures and distributes eye care products, ranging from surgical and prescription medicines through to dry eye drops and nutritional supplements for eye health.
Founded in 2007 with just two entrepreneurial employees, Philip Lewis Williams and Helen Owens, the firm now employs close to sixty people. The past ten years of global success can be attributed to the innovative approach in bringing preservative free solutions to eye care. For Thea the past decade has been one of education, strong new relationships and a successful business built on the company’s founding principles of Innovation, Education and Professionalism.
To find out more about space at Keele University Science and Innovation Park, visit https://www.keele.ac.uk/business/scienceandinnovationpark/
- New tool developed by Keele and Oxford scientists could help GPs predict and prevent serious falls
- Keele helps businesses 'deliver genuine solutions to real-world problems'
- Fresh direction for Keele Business School with new Director and suite of new courses
- Calls for international effort to study impact of textile industry on rivers and lakes
- Older musculoskeletal pain patients are at greater risk of worse outcomes from heart attack, stroke, and cancer